Slide 1: Vopimetostat and RAS(ON) combination data
Vopimetostat and RAS(ON) combination data June 8, 2026
Slide 2: Disclaimer and safe harbor statement
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or
Slide 3: Agenda for today
Agenda for today Leader in PRMT5 targeted therapy for cancer Malte Peters, MD | President and Chief Executive Officer Vopimetostat + RAS(ON) combination data show transformative potential in pancreatic cancer Brian Wolpin, MD | Dana-Farber Cancer Institute & Harvard Medical School Strategy to accele
Slide 4: Leader in PRMT5 targeted therapy for cancer
Leader in PRMT5 targeted therapy for cancer Malte Peters, MD, President and Chief Executive Officer 4
Slide 5: At the forefront of transformative shift in pancreatic cancer treatment
At the forefront of transformative shift in pancreatic cancer treatment Transformative Clear strategy Scientific leader for front line development in PRMT5 inhibition 92% ORR in 2/3L PDAC with chemotherapy free in combination with daraxonrasib regimen Near-term focus on potential blockbuster PDAC op
Slide 6: ~60,000 patients with MTAP del metastatic cancers annually in the US
~60,000 patients with MTAP del metastatic cancers annually in the US MTAP del % Number of cases NSCLC 15% Plan to initially prioritize PDAC Pancreatic 40% GBM/glioma 45% • Potential blockbuster opportunity for Head and Neck 16% vopimetostat in PDAC alone Bladder 25% − Nearly all patients with an MTA
Slide 7: Brian Wolpin is a leader in the study and treatment of pancreatic cancer
Brian Wolpin is a leader in the study and treatment of pancreatic cancer Professor of Medicine, Harvard Medical School Robert T. & Judith B. Hale Chair in Pancreatic Cancer, Dana-Farber Cancer Institute Director, Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Cen
Slide 8: Vopimetostat + RAS(ON) combination data show transformative potential in pancreatic cancer
Vopimetostat + RAS(ON) combination data show transformative potential in pancreatic cancer Dr. Brian Wolpin, MD, MPH Dana-Farber Cancer Institute & Harvard Medical School 8
Slide 9: Evolution of standard of care for pancreatic cancer
Evolution of standard of care for pancreatic cancer CHEMOTHERAPY RAS INHIBITORS1 RAS INHIBITORS + PRMT5 INHIBITORS Current standard; Improved response Increased response rate and Limited efficacy and durability prolonged durability Today Emerging Potential Next Generation 1. Wolpin et al. ASCO, 2026
Slide 10: Vopimetostat selectively inhibits the cell essential gene PRMT5 in MTAP deleted cancer cells
Vopimetostat selectively inhibits the cell essential gene PRMT5 in MTAP deleted cancer cells X deletion causes MTA accumulation only in cancer cells X MTAP MTA MTA activates PRMT5 partially inhibits PRMT5 SAM MTA MTA by replacing SAM in normal cells Vopimetostat PRMT5 inhibits PRMT5 only in MTAP-del
Slide 11: PRMT5 + RAS inhibition demonstrated preclinical synergy
PRMT5 + RAS inhibition demonstrated preclinical synergy In vivo model demonstrated striking combination efficacy Key points MTAP-null, KRASG12D PDAC CDX (KP4) • KRAS inhibition + PRMT5 inhibition is synergistic in multiple preclinical models1 • Clinical data to date support synergy of combination in
Slide 12: Vopimetostat + panRAS inhibition may yield maximal synergy
Vopimetostat + panRAS inhibition may yield maximal synergy panRAS inhibition may result in maximal synergy G12D specific inhibition may allow partial rescue by wtRAS Compensatory vopimetostat daraxonrasib vopimetostat zoldonrasib wtRAS Signaling PRMT5 RAS PRMT5 KRAS G12D wtRAS Disrupted Disrupted De
Slide 13: First PRMT5 inhibitor combined with RAS inhibitors in the clinic
First PRMT5 inhibitor combined with RAS inhibitors in the clinic Phase 1 dose escalation trial Vopimetostat + daraxonrasib: • Dose escalation range: Any RAS mut vopimetostat + 200 mg – 250 mg vopimetostat QD 2L+ MTAP-del/ daraxonrasib + 100 mg daraxonrasib QD RAS mut pancreatic and lung cancer vopim
Slide 14: Patient baseline characteristics
Patient baseline characteristics vopimetostat + Vopimetostat + vopimetostat + daraxonrasib daraxonrasib zoldonrasib (PDAC) (NSCLC) (PDAC) N 20 5 34 Sex, male, n (%) 9 (45) 3 (60) 18 (53) Age, years, median (range) 66 (46-74) 55 (38-71) 66 (37-81) Number of prior lines of systemic therapy in metastat
Slide 15: Best Overall Response: vopimetostat + daraxonrasib in 2/3L PDAC
Vopimetostat + daraxonrasib in MTAPdel 2/3L PDAC: ORR 92% - 11 PRs in 12 patients 20 Line of therapy: N=12 2 2 2 3 3 2 3 3 3 3 1 2 0 ORR 92% DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL2 DL1 DL2 Best Overall Response (%) DCR 100% -20 * • 9 cPR • 2 uPR pending confirmation -40 Best Objective Response: -60
Slide 16: Best Overall Response: vopimetostat + daraxonrasib in NSCLC and PDAC
Vopimetostat + daraxonrasib in MTAPdel NSCLC and PDAC: ORR 93% - 14 PRs in 15 patients 20.0 Line of therapy: N=15 2 2 2 3 3 2 4 3 3 3 3 3 1 3 2 .0 ORR 93% DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL1 DL1 DL2 Best Overall Response (%) DCR 100% -20.0 * • 12 cPR • 2 uPR pending confirmation -40.
Slide 17: Encouraging durability with vopimetostat + daraxonrasib
Encouraging durability with vopimetostat + daraxonrasib Line of Indication therapy PDAC 3 Key Metrics NSCLC 3 PDAC 3 • Two disease progressions PDAC 3 observed PDAC 2 PDAC 3 • Longest treatment ~10 months, ongoing PDAC 3 PDAC 2 ∗ • Median PFS NR (NE-NE) PDAC 2 • 90% 6-month PFS rate in PDAC 2 PDAC (
Slide 18: 72 year old woman with MTAPdel, KRAS-G12R metastatic pancreatic cancer
72 year old woman with MTAPdel, KRAS-G12R metastatic pancreatic cancer who received vopimetostat + daraxonrasib in the 3L setting Cycle 7, day 1: Baseline cPR (-52%) Response ongoing Data extract 28 May 2026. 3L, third line; cPR, confirmed partial response. 18
Slide 19: Vopimetostat + daraxonrasib was generally well tolerated
Vopimetostat + daraxonrasib was generally well tolerated Dose level 1 Dose level 1 Dose level 2 Safety Summary 200 mg vopimetostat + 200 mg vopimetostat + 250 mg vopimetostat + 100 mg daraxonrasib 100 mg daraxonrasib 100 mg daraxonrasib • No new safety signals observed PDAC, N=16 NSCLC, N=5 PDAC, N=
Slide 20: Vopimetostat + daraxonrasib has favorable RAS associated safety profile
Vopimetostat + daraxonrasib has favorable RAS associated safety profile vopimetostat 200 mg + daraxonrasib 100 mg (PDAC and lung) Pharmacokinetics and safety n=21 (TRAEs, % patients) dose level 1 Rash • Daraxonrasib AUC: 4106 hr*ng/ml (n=13, CV 40.5%) Stomatitis/Mucositis - Similar to daraxonrasib 3
Slide 21: First PRMT5 inhibitor combined with RAS inhibitors in the clinic
First PRMT5 inhibitor combined with RAS inhibitors in the clinic Phase 1 dose escalation trial Vopimetostat + zoldonrasib: • Dose escalation range: Any RAS mut vopimetostat + 200 – 250 mg vopimetostat QD + 2L+ MTAP-del/ daraxonrasib 600 – 1200 mg zoldonrasib QD RAS mut pancreatic and lung cancer vop
Slide 22: Vopimetostat + zoldonrasib was generally well tolerated
Vopimetostat + zoldonrasib was generally well tolerated Safety Summary All dose levels vopimetostat + zoldonrasib • No new safety signals observed N=34 • No discontinuations due to AEs All grades Grade 3 • One dose reduction TRAEs ≥15% • Most AEs were Grade 1 or 2 Patients with any event 28 (82) 9 (
Slide 23: Best Overall Response: vopimetostat + zoldonrasib in KRAS G12D 2/3L PDAC
Vopimetostat + zoldonrasib in MTAPdel KRAS G12D 2/3L PDAC: ORR 52% - 14 PRs in 27 patients 20 Line of therapy: 3 3 3 3 3 3 3 3 3 3 2 2 3 2 3 2 3 2 3 3 3 2 2 3 2 3 2 DL1 0 DL3 DL2 DL2 DL2 DL3 DL1 DL4 DL2 DL1 DL3 DL2 DL1 DL3 DL2 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL4 DL1 DL1 DL1 DL1 N=27 Best Overall Respons
Slide 24: Combined ORR 64% in 2/3L PDAC demonstrates clinical synergy
Combined ORR 64% in 2/3L PDAC demonstrates clinical synergy of vopimetostat + RAS(ON) inhibition N=39 20 PD ORR 64% 0 DCR 97% SD SD Best Overall Response (%) -20 SD SD SD SD SD SD SD SD PR PR PR PR PR PR -40 PR SD PR PR SD SD PR PR PR PR PR PR PR PR PR PR -60 PR PR Vopimetostat + zoldonrasib, PDAC -
Slide 25: Strategy to accelerate registration-directed development of vopimetostat
Strategy to accelerate registration-directed development of vopimetostat Adam Crystal, MD PhD, President of Research and Development 25
Slide 26: Tango's strategy to develop vopimetostat + daraxonrasib combination for pancreatic cancer
Tango's strategy to potentially develop vopimetostat + daraxonrasib combination for patients with pancreatic cancer 1 Assess contribution of components Expansion of Primary Phase 1/2 study Readout 2 Explore accelerated 2L approval Primary 1L RCT Readout 3 1L approval Plan to engage global regulatory
Slide 27: Capital allocation plan and financial highlights
Capital allocation plan and financial highlights Matthew Gall, Chief Financial Officer 27
Slide 28: Disciplined capital allocation focused on most promising, value-creating opportunities
Disciplined capital allocation focused on most promising, value-creating opportunities Clear path forward Multiple inflection points anticipated by end of 2026 Rapidly advance 1L PDAC vopimetostat + Finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pa
Slide 29: Closing remarks
Closing remarks Malte Peters, MD, Chief Executive Officer 29
Slide 30: At the forefront of transformative shift in pancreatic cancer treatment
At the forefront of transformative shift in pancreatic cancer treatment Transformative Clear strategy Scientific leader for front line development in PRMT5 inhibition 92% ORR in 2/3L PDAC with chemotherapy free in combination with daraxonrasib regimen Near-term focus on potential blockbuster PDAC op
Slide 31: CONFIDENTIAL
Ai; TANGO therapeutics CONFIDENTIAL